Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
Iovance Biotherapeutics Inc (NASDAQ: IOVA) closed the day trading at $11.32 up 0.09% from the previous closing price of $11.31. In other words, the price has increased by $0.09 from its previous closing price. On the day, 2.4 million shares were traded. IOVA stock price reached its highest trading level at $11.635 during the session, while it also had its lowest trading level at $11.07.
Ratios:
For a better understanding of IOVA, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.70 and its Current Ratio is at 2.79. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.12.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on November 20, 2023, initiated with a Buy rating and assigned the stock a target price of $12.
On September 18, 2023, Barclays reiterated its Overweight rating and also upped its target price recommendation from $40 to $18.
Wells Fargo Upgraded its Equal Weight to Overweight on May 30, 2023, whereas the target price for the stock was revised from $11 to $17.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 20 ’24 when Rothbaum Wayne P. bought 5,000,000 shares for $9.15 per share. The transaction valued at 45,750,000 led to the insider holds 28,067,333 shares of the business.
MCPEAK MERRILL A bought 250,000 shares of IOVA for $2,287,500 on Feb 20 ’24. The Director now owns 320,150 shares after completing the transaction at $9.15 per share. On Feb 20 ’24, another insider, Dukes Iain D., who serves as the Director of the company, bought 32,000 shares for $9.15 each. As a result, the insider paid 292,800 and bolstered with 54,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IOVA now has a Market Capitalization of 3161755136 and an Enterprise Value of 2957753600. For the stock, the TTM Price-to-Sale (P/S) ratio is 2656.97 while its Price-to-Book (P/B) ratio in mrq is 4.96. Its current Enterprise Value per Revenue stands at 2487.598 whereas that against EBITDA is -6.587.
Stock Price History:
The Beta on a monthly basis for IOVA is 0.68, which has changed by 1.0544465 over the last 52 weeks, in comparison to a change of 0.23061275 over the same period for the S&P500. Over the past 52 weeks, IOVA has reached a high of $18.33, while it has fallen to a 52-week low of $3.21. The 50-Day Moving Average of the stock is -17.70%, while the 200-Day Moving Average is calculated to be 38.99%.
Shares Statistics:
Over the past 3-months, IOVA traded about 9.10M shares per day on average, while over the past 10 days, IOVA traded about 4442160 shares per day. A total of 256.14M shares are outstanding, with a floating share count of 220.05M. Insiders hold about 21.21% of the company’s shares, while institutions hold 67.26% stake in the company. Shares short for IOVA as of 1711584000 were 46378639 with a Short Ratio of 5.10, compared to 1709164800 on 46706133. Therefore, it implies a Short% of Shares Outstanding of 46378639 and a Short% of Float of 17.930001.
Earnings Estimates
At present, 12 analysts are actively evaluating the performance of Iovance Biotherapeutics Inc (IOVA) in the stock market.On average, analysts expect EPS of $-0.42 for the current quarter, with a high estimate of $-0.32 and a low estimate of $-0.5, while EPS last year was $-0.5. The consensus estimate for the next quarter is $-0.36, with high estimates of $-0.15 and low estimates of $-0.45.
Analysts are recommending an EPS of between $-0.47 and $-1.8 for the fiscal current year, implying an average EPS of $-1.29. EPS for the following year is $-0.71, with 12 analysts recommending between $0.34 and $-1.58.
Revenue Estimates
12 analysts predict $2.07M in revenue for the current quarter. It ranges from a high estimate of $6M to a low estimate of $480k. As of the current estimate, Iovance Biotherapeutics Inc’s year-ago sales were $200k, an estimated increase of 935.00% from the year-ago figure. For the next quarter, 12 analysts are estimating revenue of $28.6M, an increase of 11,916.80% over than the figure of $935.00% in the same quarter last year. There is a high estimate of $60.6M for the next quarter, whereas the lowest estimate is $5.2M.
A total of 12 analysts have provided revenue estimates for IOVA’s current fiscal year. The highest revenue estimate was $277.5M, while the lowest revenue estimate was $33.2M, resulting in an average revenue estimate of $162.27M. In the same quarter a year ago, actual revenue was $1.19M, up 13,547.60% from the average estimate. Based on 12 analysts’ estimates, the company’s revenue will be $418.63M in the next fiscal year. The high estimate is $744.18M and the low estimate is $130.5M. The average revenue growth estimate for next year is up 158.00% from the average revenue estimate for this year.
